Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasm Metastasis 2Sarcoma, Synovial 1Sarcoma 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Oropharyngeal Neoplasms 1Neuroendocrine Tumors 1Neoplasms 1Mouth Neoplasms 1Lymphatic Metastasis 1Liposarcoma 1Leukemia, Myeloid, Acute 1Leiomyosarcoma 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Histiocytoma, Malignant Fibrous 1Gliosarcoma 1Glioblastoma 1Gallbladder Neoplasms 1Fallopian Tube Neoplasms 1Dermatofibrosarcoma 1Cholangiocarcinoma 1Carcinoma 1

Interventions

Gemcitabine 57130-nm albumin-bound paclitaxel 35Specimen Handling 26Magnetic Resonance Spectroscopy 21Albumin-Bound Paclitaxel 21Fluorouracil 20Leucovorin 19Irinotecan 19Oxaliplatin 17Biopsy 17Taxes 16pembrolizumab 13Cyclophosphamide 11Cisplatin 11fludarabine 10Cetuximab 9Capecitabine 8Nivolumab 7Carboplatin 7irinotecan sucrosofate 6durvalumab 6dehydroftorafur 6Radiosurgery 6Pemetrexed 6olaparib 5Ipilimumab 5Erlotinib Hydrochloride 5trastuzumab deruxtecan 4aldesleukin 4Radiotherapy 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pancreatic Neoplasms × peposertib × 90 days × Clear all
NCT04172532 2026-06-02

Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer

National Cancer Institute (NCI)

Phase 1/2 Recruiting
92 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡